201 related articles for article (PubMed ID: 36618419)
1. The safety of COVID-19 vaccines in patients with myasthenia gravis: A scoping review.
Peng S; Tian Y; Meng L; Fang R; Chang W; Yang Y; Li S; Shen Q; Ni J; Zhu W
Front Immunol; 2022; 13():1103020. PubMed ID: 36618419
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience.
Farina A; Falso S; Cornacchini S; Spagni G; Monte G; Mariottini A; Massacesi L; Barilaro A; Evoli A; Damato V
Eur J Neurol; 2022 Aug; 29(8):2505-2510. PubMed ID: 35390184
[TBL] [Abstract][Full Text] [Related]
3. Safety of mRNA COVID-19 vaccines in patients with well-controlled myasthenia gravis.
Gamez J; Gamez A; Carmona F
Muscle Nerve; 2022 Nov; 66(5):612-617. PubMed ID: 36029224
[TBL] [Abstract][Full Text] [Related]
4. Early safety and tolerability profile of the BNT162b2 COVID-19 vaccine in myasthenia gravis.
Lotan I; Hellmann MA; Friedman Y; Stiebel-Kalish H; Steiner I; Wilf-Yarkoni A
Neuromuscul Disord; 2022 Mar; 32(3):230-235. PubMed ID: 35227552
[TBL] [Abstract][Full Text] [Related]
5. Vaccines and myasthenia gravis: a comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients.
Sansone G; Bonifati DM
J Neurol; 2022 Aug; 269(8):3965-3981. PubMed ID: 35503373
[TBL] [Abstract][Full Text] [Related]
6. BNT162b2 mRNA COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis during the alpha, delta, and omicron waves.
Doron A; Piura Y; Vigiser I; Kolb H; Regev K; Nesher N; Karni A
J Neurol; 2022 Dec; 269(12):6193-6201. PubMed ID: 35907046
[TBL] [Abstract][Full Text] [Related]
7. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
Beckley M; Olson AK; Portman MA
JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 vaccination in people with multiple sclerosis, real-life experience.
Alroughani R; Al-Hashel J; Abokalawa F; AlMojel M; Farouk Ahmed S
Clin Neurol Neurosurg; 2022 Sep; 220():107374. PubMed ID: 35961255
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
Lazarus R; Baos S; Cappel-Porter H; Carson-Stevens A; Clout M; Culliford L; Emmett SR; Garstang J; Gbadamoshi L; Hallis B; Harris RA; Hutton D; Jacobsen N; Joyce K; Kaminski R; Libri V; Middleditch A; McCullagh L; Moran E; Phillipson A; Price E; Ryan J; Thirard R; Todd R; Snape MD; Tucker D; Williams RL; Nguyen-Van-Tam JS; Finn A; Rogers CA;
Lancet; 2021 Dec; 398(10318):2277-2287. PubMed ID: 34774197
[TBL] [Abstract][Full Text] [Related]
10. Safety of inactivated SARS-CoV-2 vaccines in myasthenia gravis: A survey-based study.
Li HY; Shao LY; Song M; Hu SM; Yue YX; Li HF
Front Immunol; 2022; 13():923017. PubMed ID: 35990671
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
[TBL] [Abstract][Full Text] [Related]
12. Coincidental Onset of Ocular Myasthenia Gravis Following ChAdOx1 n-CoV-19 Vaccine against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Galassi G; Rispoli V; Iori E; Ariatti A; Marchioni A
Isr Med Assoc J; 2022 Jan; 24(1):9-10. PubMed ID: 35077038
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of intradermal administration of fractional dose CoronaVac
Chatsiricharoenkul S; Niyomnaitham S; Posen HJ; Toh ZQ; Licciardi PV; Wongprompitak P; Duangchinda T; Pakchotanon P; Chantima W; Chokephaibulkit K
Front Immunol; 2022; 13():1010835. PubMed ID: 36268028
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
15. An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.
Isnardi CA; Schneeberger EE; Kreimer JL; Luna PC; Echeverría C; Roberts K; de la Vega MC; Virasoro BM; Landi M; Quintana R; Exeni MED; Kogan N; Petkovic I; Pereira D; De Los Ángeles Correa M; Zelaya MD; Tissera Y; Elkin MSG; Pisoni CN; Alonso C; Cogo AK; Cosatti MA; García L; Retamozo C; de Los Ángeles Severina M; Nieto RE; Rosemffet M; Mussano E; Bertoli A; Savio VG; Cosentino V; Pons-Estel GJ
Clin Rheumatol; 2022 Oct; 41(10):3199-3209. PubMed ID: 35760939
[TBL] [Abstract][Full Text] [Related]
16. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
[TBL] [Abstract][Full Text] [Related]
17. Safety and neutralization antibody levels of inactivated SARS-CoV-2 vaccine in adult patients with Myasthenia Gravis: a prospective observational cohort study.
Zheng W; Cao X; Luo J; Liu Z; Que W; Guo X; Fan R; Long Q; Xiao F
Neurol Sci; 2024 Apr; 45(4):1707-1717. PubMed ID: 37940750
[TBL] [Abstract][Full Text] [Related]
18. Flare of myasthenia gravis induced by COVID-19 vaccines.
Ishizuchi K; Takizawa T; Sekiguchi K; Motegi H; Oyama M; Nakahara J; Suzuki S
J Neurol Sci; 2022 May; 436():120225. PubMed ID: 35290838
[No Abstract] [Full Text] [Related]
19. Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study.
Ruan Z; Huan X; Su Y; Tang YL; Meng DD; Ren DL; Li CH; Hao SJ; Zhao CB; Luo SS; Li ZY; Chang T
Front Immunol; 2023; 14():1141983. PubMed ID: 37223097
[TBL] [Abstract][Full Text] [Related]
20. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.
Jarius S; Bieber N; Haas J; Wildemann B
J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
